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LETTER TO THE EDITORS
Letter concerning “Enzyme replacement therapy
in a patient with Fabry disease and the development
of IgE antibodies against agalsidase beta
but not agalsidase alpha”, by Tanaka et al.
Gabor E. Linthorst & Johannes M. F. G. Aerts
# The Author(s) 2010. This article is published with open access at Springerlink.com
Dear editor,
Recently, Tanaka and co-workers published a report in the
Journal of Inherited Metabolic Disorders on the treatment
of a young male with Fabry disease who developed an
immunoglobulin E (IgE) response toward one of the two
available enzyme preparations (agalsidase beta) but not to
the other (agalsidase alpha) (Tanaka et al. 2010). As has
been shown by several groups, the emergence of IgG
antibodies toward the infused enzyme alpha galactosidase
occurs frequently in male Fabry disease patients (Linthorst
et al. 2004; Whitfield et al. 2005; Ohashi et al. 2007),
irrespective of the enzyme preparation used. In these
studies, cross-reactivity was shown: in anti-agalsidase
IgG-positive patients, these antibodies were always equally
reactive toward either agalsidase alpha or beta, again
irrespective of the enzyme preparation given to the patient.
The presence of anti-agalsidase IgG results in less urinary
GL-3 clearance and is associated with infusion-associated
events (Linthorst et al. 2004, 2006).
The study by Tanaka et al. is interesting for two reasons:
First, the patient had a known severe atopy, and this led the
authors to decide to monitor anti-agalsidase IgG and IgE
levels routinely between infusions. Following the first
infusion of agalsidase beta of 1 mg/kg, a positive anti-
agalsidase beta IgE result was obtained. The authors do not
mention the anti-agalsidase IgG status. The emergence of
anti-agalsidase IgE after the first infusion is remarkably
early, as most anti-agalsidase (IgG) antibodies will be
detectable between infusions four and 12 (e.g., months 2–6).
The patient’s atopy may have contributed to the early
immunization toward agalsidase beta. Second, this is the first
case in which no cross-reactivity is reported for antibodies
between agalsidase beta and alpha. Unfortunately no anti-
agalsidase IgE titers are mentioned, and it is not known how
the authors determined anti-agalsidase IgE. Was the same
assay employed using the two different enzymes to capture
(and determine) the actual presence of anti-agalsidase IgE?
Did the authors use an in-house assay, or was the antibody
status measured by the respective manufacturers of agalsidase
alpha and beta? As a service to the medical community, both
producers of agalsidase alpha (Replagal, Shire Inc.) and beta
(Fabrazyme, Genzyme Corp.) measure anti-agalsidase IgG
and IgE in plasma from patients treated with their products.
Substantial differences on the presence (or absence) of anti-
agalsidase IgG in the assays employed by the two companies
have become apparent. This observation resulted in an
initiative to develop a uniform method to measure, quantify,
and report antibody status (Schellekens 2008). This initiative
is sponsored by the two involved companies and is joined by
several academic laboratories. Its results are eagerly awaited.
Such a uniform assay will aid greatly the ability to discern
possible differences in antibody response toward the two
products.
The possibility that some anti-agalsidase IgG or IgE
antibodies may not be cross-reactive offers hope for those
who develop such antibodies and subsequently may
develop severe infusion reactions or reduced efficacy.
However, it is imperative that the findings of Tanaka et al.
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alpha and beta. Only then can a true comparison be made.
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